Azopax Therapeutics, Inc. is an emerging specialty pharmaceutical company developing sophisticated time-release, injectable, microsphere formulations, which enable improved delivery of pharmaceutical and biopharmaceutical products. Azopax's product pipeline of 2nd generation protein and peptide drugs is focused upon treatment of diabetes, cancer, obesity and endocrine disorders. Unlike other drug delivery technologies, Azopax's microsphere formulations deliver protein and peptide drugs without burst (high initial peak levels, which cause side effects); with the steady blood levels required for optimal efficacy; and with other product features required for superior performance.